<DOC>
	<DOCNO>NCT02175004</DOCNO>
	<brief_summary>This study evaluate safety tolerability extend dose IONIS-TTR Rx patient Familial Amyloid Polyneuropathy .</brief_summary>
	<brief_title>Open-Label Extension Assessing Long Term Safety Efficacy IONIS-TTR Rx Familial Amyloid Polyneuropathy ( FAP )</brief_title>
	<detailed_description>Familial Amyloid Polyneuropathy ( FAP ) rare , hereditary disease cause mutation transthyretin ( TTR ) protein . TTR make liver secrete blood . TTR mutation cause misfold deposit multiple organ cause FAP . IONIS-TTR Rx antisense drug design decrease amount mutant normal TTR make liver . It predict decrease amount TTR protein result decrease formation TTR deposit , thus slow stop disease progression . This study evaluate safety tolerability extend dose IONIS-TTR Rx patient Familial Amyloid Polyneuropathy .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies</mesh_term>
	<mesh_term>Amyloid Neuropathies , Familial</mesh_term>
	<criteria>Satisfactory completion dose &amp; efficacy assessment ISIS 420915CS2 Any new condition worsen exist condition could make patient unsuitable participation , interfere patient participate and/or complete study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>FAP</keyword>
	<keyword>Familial Amyloid Polyneuropathy</keyword>
	<keyword>TTR</keyword>
	<keyword>Transthyretin</keyword>
	<keyword>Amyloidosis</keyword>
</DOC>